Biogen Details $5.6B Apellis Deal, Sees Mid-to-High-Teens Growth and EPS Accretion by 2027
Corroborated by 4 sources from 4 publishers
TL;DR
Reports differ across sources; according to finance.yahoo.com, key Points - Biogen will acquire Apellis for $41 per share (about $5.6 billion upfront) plus contingent value rights, with the deal expected to close in Q2 2026 and financed via cash, revolver borrowings and a bank term loan (transaction borrowings targeted to be repaid by end of 2027).
Sources
1
Biogen.com
https://investors.biogen.com/news-releases/news-release-details/biogen-acquire-apellis-enhancing-companys-growth-portfolio
2
Yahoo Finance News
https://finance.yahoo.com/sectors/healthcare/articles/biogen-details-5-6b-apellis-141037757.html
3
Yahoo Finance News
https://finance.yahoo.com/sectors/healthcare/articles/biogen-acquire-apellis-pharmaceuticals-5-162000353.html
4
Investor's Business Daily
https://www.investors.com/news/technology/biogen-apellis-pharmaceuticals-buyout-syfovre-empaveli
5
Yahoo Finance News
https://finance.yahoo.com/markets/stocks/articles/apellis-pharma-skyrockets-biogen-deal-193840636.html
6
Bloomberg Markets
https://www.bloomberg.com/news/videos/2026-04-01/biogen-buys-apellis-for-5-6b-to-expand-kidney-drugs-video